Dennis Björk

Dr. Dennis Björk

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in British Journal of Surgery
Verified
Journal Article
Open access
TRTim Reese
Tim Reese
DBDennis Björk
Dennis Björk
ALAnne M H Longva
Anne M H Longva
KKKristian S Kiim
Kristian S Kiim
MEMaximilian Evers
Maximilian Evers
ESErnesto Sparrelid
Ernesto Sparrelid
Background: Upfront portal vein embolization (PVE) without prior future liver remnant (FLR) clearing followed by a one-stage hepatectomy (OSH) for bilateral colorectal liver metastases (CRLM) can reduce the surgical burden of a two-stage approach, but oncological safety is not well described and comparisons with alternative two-stage procedures are lacking. Methods: A retrospective cohort of patients with bilateral CRLM and tumour in the FLR, undergoing liver resection between 2013 and 2021, was studied. The patients were divided into three groups: patients who underwent PVE with no prior tumour clearance in the FLR followed by an OSH (PVE-OSH); patients who underwent tumour clearance in the FLR followed by PVE (TSH-PVE; where TSH stands for two-stage hepatectomy); and patients who underwent associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Results: In total, 302 patients with bilateral CRLM were included, of whom 127 underwent PVE-OSH, 61 underwent TSH-PVE, and 114 underwent ALPPS. Except for age and Eastern Cooperative Oncology Group (ECOG) Performance Status, all baseline characteristics were comparable. The most rapid hypertrophy was experienced by ALPPS patients, followed by PVE-OSH patients. Successful resection could not be performed in 11% of PVE-OSH patients, 21% of TSH-PVE patients, and 4% of ALPPS patients (P < 0.001). During major resection, 23% of TSH-PVE patients required additional FLR resection/ablation and the median time from first intervention to major resection was 9 (interquartile range (i.q.r.) 7–13) weeks, compared with 6 (i.q.r. 5–8) weeks for PVE-OSH patients and 1 (i.q.r. 1–3) week for ALPPS patients (P < 0.001). Postoperative outcomes were comparable regarding liver failure, mortality, and overall survival. Multivariable regression analysis for liver recurrence identified the number of metastases (HR 1.04 (95% c.i. 1.00 to 1.07); P = 0.025) and ALPPS (HR 1.64 (95% c.i. 1.00 to 2.68); P = 0.048) as independent risk factors. Conclusion: PVE-OSH can be performed safely for patients with a limited tumour burden in the FLR, thereby obviating the need for two-stage procedures.

22 October 2023 in Heliyon
Verified
Journal Article
Open access
DBDennis Björk
Dennis Björk
MDMartin Delle
Martin Delle
FHFredrik Holmquist
Fredrik Holmquist
KHKristina Hasselgren
Kristina Hasselgren
PSPer Sandstrom
Per Sandstrom
BBBergthor Björnsson
Bergthor Björnsson
An adequate future liver remnant (FLR) is fundamental for major liver resections. To achieve sufficient FLR, portal vein embolization (PVE) may be used. The most effective material for PVE has yet to be determined. The aim of this study was to investigate the differences in FLR growth between n-butyl-cyanoacrylate glue (NBCA) and microparticles. retrospective study was performed at three Swedish hepatobiliary centers and included patients who underwent PVE 2013–2021. Electronic medical records were reviewed, and procedure-related data were collected. Data were analyzed with respect to embolizing material. A total of 265 patients were included: 160 in the NBCA group and 105 in the microparticle group. The NBCA group had a higher degree of hypertrophy (12.1 vs. 9.4 % points, p = 0.003) and a higher resection rate (68 vs. 59 %, p = 0.01) than the microparticle group. Procedure-related data all indicated the superiority of NBCA. No difference in inducing hypertrophy was observed when comparing patients who received chemotherapy before PVE with those who received chemotherapy before and after PVE within the NBCA group. This retrospective multicenter study supports the superiority of NBCA compared to microparticles in the setting of PVE. Chemotherapy after PVE does not seem to negatively affect hypertrophy.

10 December 2024 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
QWQiang Wang
Qiang Wang
TBTorkel B. Brismar
Torkel B. Brismar
DBDennis Björk
Dennis Björk
EFErik Baubeta Fridh
Erik Baubeta Fridh
GLGert Lindell
Gert Lindell
ESErnesto Sparrelid
Ernesto Sparrelid
Objectives: This study aimed to develop and externally validate a model for predicting insufficient future liver remnant (FLR) hypertrophy after portal vein embolization (PVE) based on clinical factors and radiomics of pretreatment computed tomography (CT) Patients and methods: Clinical information and CT scans of 241 consecutive patients from three Swedish centers were retrospectively collected. One center (120 patients) was applied for model development, and the other two (59 and 62 patients) as test cohorts. Logistic regression analysis was adopted for clinical model development. A FLR radiomics signature was constructed from the CT images using the support vector machine. A model combining clinical factors and FLR radiomics signature was developed. Area under the curve (AUC) was adopted for predictive performance evaluation Results: Three independent clinical factors were identified for model construction: pretreatment standardized FLR (odds ratio (OR): 1.12, 95% confidence interval (CI): 1.04–1.20), alanine transaminase (ALT) level (OR: 0.98, 95% CI: 0.97–0.99), and PVE material (OR: 0.27, 95% CI: 0.08–0.87). This clinical model showed an AUC of 0.75, 0.71, and 0.68 in the three cohorts, respectively. A total of 833 radiomics features were extracted, and after feature dimension reduction, 16 features were selected for FLR radiomics signature construction. When adding it to the clinical model, the AUC of the combined model increased to 0.80, 0.76, and 0.72, respectively. However, the increase was not significant. Conclusions: Pretreatment CT radiomics showed added value to the clinical model for predicting FLR hypertrophy following PVE. Although not reaching statistically significant, the evolving radiomics holds a potential to supplement traditional predictors of FLR hypertrophy.

22 March 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
DBDennis Björk
Dennis Björk
UCUlrik Carling
Ulrik Carling
SGStefan Gilg
Stefan Gilg
KHKristina Hasselgren
Kristina Hasselgren
PLPeter N. Larsen
Peter N. Larsen
BBBergthor Björnsson
Bergthor Björnsson
Portal vein embolization (PVE) may be used to induce hypertrophy of the future liver remnant (FLR) before major hepatectomy. The influence of hyperbilirubinemia on FLR hypertrophy after PVE is controversial. The aim of this study was to compare FLR hypertrophy after PVE between patients with and without elevated P-bilirubin. This is a Scandinavian retrospective cohort study of patients from five hepatobiliary centres. This study included patients who underwent right-sided PVE from 2013 to 2023. Data were collected from electronic medical records. FLR growth was analysed with respect to normal or elevated P-bilirubin. In total, 410 patients were included in this study. Among the total cohort, 105 patients had elevated P-bilirubin levels (≥26 μmol/L) at the time of PVE. Elevated P-bilirubin levels were not associated with impaired FLR hypertrophy after PVE, as determined by absolute growth (p < 0.001), relative growth (p = 0.008), degree of hypertrophy (p < 0.001) and kinetic growth rate (p = 0.002). Multivariable analysis revealed that elevated P-bilirubin levels at the time of PVE (p = 0.002) together with the use of N-butyl cyanoacrylate (NBCA) as an embolizing material (p = 0.009) were associated with increased FLR hypertrophy. A larger estimated total liver volume was associated with reduced FLR hypertrophy (p < 0.001). In this multicentre, retrospective cohort study, we were unable to show any negative effect of elevated P-bilirubin on FLR hypertrophy at the time of PVE. There is no need for P-bilirubin levels to normalize before PVE. This study supports the ongoing shift towards NBCA as an embolizing material.

7 December 2024 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
QWQiang Wang
Qiang Wang
TBTorkel B. Brismar
Torkel B. Brismar
DBDennis Björk
Dennis Björk
EFErik Baubeta Fridh
Erik Baubeta Fridh
GLGert Lindell
Gert Lindell
ESErnesto Sparrelid
Ernesto Sparrelid

25 September 2026 in HPB
Verified
Journal Article
Open access
KJKarin Johansen
Karin Johansen
JFJacob Freedman
Jacob Freedman
DBDennis Björk
Dennis Björk
PSPer Sandstrom
Per Sandstrom
BBBergthor Björnsson
Bergthor Björnsson
This study aimed to compare survival after surgery among elderly patients with pancreatic and periampullary tumours with patients who were offered resection but declined. Data were obtained from the Swedish national registry for tumours in the pancreatic and periampullary region 2010-2022 for patients ≥80 years. Patients were excluded who were not eligible for upfront resection or who had missing data regarding treatment decision. Remaining patients were compared between one group that underwent surgery and one group that was offered surgery but declined. Out of 3991 patients, 467 remained after the selection, of whom 360 underwent surgery and 107 declined. Patients who declined surgery were a median two years older and had higher rates of pulmonary disease, peptic ulcer disease and heart failure. Charlson Comorbidity Index was comparable between groups. The median overall survival was 2.2 years after surgery and 0.8 years without surgery. Significant factors in the multivariable analysis for overall survival were surgery, age and diagnosis. The group undergoing surgery had significantly longer overall survival, although this must be interpreted in the light of baseline differences between groups and possible selection bias. This study may serve as an aid for preoperative counseling.